Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved ziftomenib, marketed as Komzifti by Kura Oncology, for adults with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.
Ziftomenib is a menin inhibitor, part of a class aimed at genetically defined leukemias.
The approval adds another example of precision oncology moving deeper into hematologic malignancies.
Why It Matters
Genetic subtyping is increasingly central to AML treatment decisions, especially after relapse.
What to Watch
Watch testing access, sequencing with other targeted therapies and durability in post-approval use.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAAMLNPM1Precision Oncology